Skip to main content
Premium Trial:

Request an Annual Quote

Tom Civik

Tom Civik has been appointed as chief commercial officer of Foundation Medicine and will start his new position in mid November. Most recently, he was a vice president and franchise leader at Genentech, where he was responsible for several oncology products. Earlier, he held various commercial positions at Sanofi-Synthelabo. Civik holds a BA from St. Norbert College and a master's degree in business administration from the Kellogg School of Management at Northwestern University.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.